Division of Hematology/Oncology, Boston Children's Hospital; Department of Pediatric Oncology, Dana-Farber Cancer Institute; Harvard Stem Cell Institute; Broad Institute; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Genome Med. 2021 Mar 10;13(1):41. doi: 10.1186/s13073-021-00857-3.
Genome-wide association studies (GWAS) have uncovered thousands of genetic variants that influence risk for human diseases and traits. Yet understanding the mechanisms by which these genetic variants, mainly noncoding, have an impact on associated diseases and traits remains a significant hurdle. In this review, we discuss emerging experimental approaches that are being applied for functional studies of causal variants and translational advances from GWAS findings to disease prevention and treatment. We highlight the use of genome editing technologies in GWAS functional studies to modify genomic sequences, with proof-of-principle examples. We discuss the challenges in interrogating causal variants, points for consideration in experimental design and interpretation of GWAS locus mechanisms, and the potential for novel therapeutic opportunities. With the accumulation of knowledge of functional genetics, therapeutic genome editing based on GWAS discoveries will become increasingly feasible.
全基因组关联研究 (GWAS) 已经发现了数千种影响人类疾病和特征风险的遗传变异。然而,了解这些遗传变异(主要是非编码)如何影响相关疾病和特征的机制仍然是一个重大障碍。在这篇综述中,我们讨论了新兴的实验方法,这些方法正被应用于因果变异的功能研究以及从 GWAS 发现到疾病预防和治疗的转化进展。我们强调了在 GWAS 功能研究中使用基因组编辑技术来修饰基因组序列,并提供了原理验证示例。我们讨论了探究因果变异的挑战、实验设计和 GWAS 基因座机制解释中的注意点,以及新的治疗机会的潜力。随着功能遗传学知识的积累,基于 GWAS 发现的治疗性基因组编辑将变得越来越可行。